Clinical Edge Journal Scan

Seropositive RA: A strong risk factor for lung cancer


 

Key clinical point: Patients with rheumatoid arthritis (RA) were at an increased risk for lung cancer compared with the general population, with seropositivity being a strong and independent risk factor above what can be explained by smoking.

Major finding: Patients with RA vs. general population were at increased risk for lung cancer (adjusted hazard ratio [aHR] 1.70; 95% CI 1.54-1.87), with the risk being even higher among ever smokers (aHR 1.82; 95% CI 1.06-3.17) or current smokers (aHR 2.73; 95% CI 1.21-6.16) and double seropositivity being a strong and independent risk factor (aHR 6.21; 95% CI 1.47-26.33).

Study details: This was a population-based matched cohort study including 44,101 patients with RA who were individually matched with 216,495 control individuals from the general population and prospectively followed for the occurrence of lung cancer.

Disclosures: This study was funded by the Swedish Research Council and other sources. K Chatzidionysiou declared receiving consulting fees from various sources. J Askling declared serving as principal investigator and having ties with various sources.

Source: Chatzidionysiou K et al. Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking. RMD Open. 2022;8(2):e002465 (Oct 21). Doi: 10.1136/rmdopen-2022-002465

Recommended Reading

In rheumatoid arthritis, reducing inflammation reduces dementia risk
MDedge Rheumatology
ACR introduces guideline for integrative interventions in RA
MDedge Rheumatology
Retention rates high after biosimilar-to-biosimilar switch for inflammatory arthritis
MDedge Rheumatology
Doctors urge screening for autoimmune disorders for patients with celiac disease
MDedge Rheumatology
Opioids increase risk for all-cause deaths in RA vs. NSAIDs
MDedge Rheumatology
StopRA trial: Hydroxychloroquine doesn’t prevent or delay onset of rheumatoid arthritis
MDedge Rheumatology
Celiac disease linked to higher risk for rheumatoid arthritis, juvenile idiopathic arthritis
MDedge Rheumatology
New ACR vaccination guideline: Take your best shot
MDedge Rheumatology
Treatment intensification benefits early RA nonresponders in COBRA treat-to-target trial
MDedge Rheumatology
Tocilizumab more effective than etanercept in suppressing progression of joint erosion in RA
MDedge Rheumatology